$TLSI

TriSalus Life Sciences (TLSI) reported Q3 2026 revenue of $12.9M, up 11.3% YoY, and revised 2026 guidance to $46M-$48M. Gross margin improved to 86.2%, and operating losses narrowed. The company received FDA clearance for TriNav Advance and expects higher Medicare reimbursement rates. CEO Mary Szela cited commercial growth but noted slower sales rep productivity. Cash reserves stood at $41.1M post-equity offering.

TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Third Quarter 2026 Results Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration Revised 2026 revenue guidance to $46 million to $48 million Centers for Medicare & Medicaid Ser

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

Worthington Enterprises (NYSE:WOR) shares rose 15.9% in pre-market trading after reporting Q1 earnings of $0.82 per share, beating estimates of $0.75, and sales of $343.89M, exceeding expectations of $331.27M.

KB Home (KBH) rose 2% post-market on strong sector signals. Worthington Enterprises (WOR) surged 14% after Q1 earnings beat estimates. IonQ (IONQ) climbed 8% on quantum error correction milestone. TriSalus Life Sciences (TLSI) jumped 28% after FDA clearance. InnovAge (INNV) dropped 12% on secondary stock offering.

TriSalus Life Sciences (TLSI) shares rose 29% after receiving FDA 510(k) clearance for TriNav Advance, a new device for its Pressure-Enabled Drug Delivery portfolio. The device expands access to small, distal vessels and supports a broader range of embolization procedures. The company plans a limited market release soon. According to the company, the device enhances its portfolio and enables physicians to optimize therapeutic delivery in complex cases.

TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Other Events. TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery TM (PEDD TM ) Portfolio for Liver Embolization WESTMINSTER, Colo. – September 22, 2026 – TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an o

Analysts initiated coverage on several companies: StoneX started HOOD with a Buy and $170 target, HC Wainwright began TLSI with a Buy and $11 target, Needham initiated KDK with a Buy and $8 target, BMO rated DECK Underperform with a $70 target, and Cantor Fitzgerald gave SGMT an Overweight rating.

TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Second Quarter 2026 Results Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration Maintains 2026 revenue guidance of $54 million to $57 million Hosting Conferen

TriSalus Life Sciences (TLSI) will present new clinical and preclinical data at the 2026 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The presentations will highlight the capabilities of its Pressure Enabled Drug Delivery (PEDD) platform for applications in liver-directed therapies and uterine artery embolization, demonstrating the platform's versatility in enhancing therapeutic delivery across various disease states. The company's CEO, Mary Szela, and CMO, Richard Marshall, emphasized the growing body of evidence supporting PEDD's potential to improve patient outcomes by enabling more effective delivery of therapies.